Want to join the conversation?
Alex Arfaei of BMO Capital asks about 2016 GM better than expected and the drivers of this growth. $PFE said that the company ended the full year at 18.5% on cost of sales and guided a 3% increase for 2016. One of the factors driving this is Hospira and the other being productivity and cost reduction initiatives.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.